Penumbra has launched the Lightning Flash 3.0 thrombectomy system ahead of a $14.5B Boston Scientific acquisition.

Penumbra (NYSE:PEN) announced today that it launched the Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) ...

Penumbra announced the launch of the Lightning Flash 3.0 computer assisted vacuum thrombectomy (CAVT) system for the ...

Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under ...

Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a ...

Launches Indigo ® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical ...

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED ...

Pulmonary embolism, or PE, is a deadly condition causing blood clots within a patient’s lungs that has grown in prevalence during the COVID-19 pandemic. The Indigo Aspiration System with Lightning 12 ...

BOSTON, Mass. - July 27, 2016 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, ...

Boston Scientific (NYSE:BSX) today announced a definitive agreement to acquire cardiovascular disease treatment device maker ...

Now available in the U.S., RED™ 62 is engineered with optimized trackability to help navigate the complex distal vessel anatomy in the brain and deliver powerful aspiration for the removal of blood ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for ...